Abstract
Aortic valve sclerosis is defined as calcification and thickening of a trileaflet aortic valve in the absence of obstruction of ventricular outflow. Its frequency increases with age, making it a major geriatric problem. Of adults aged> 65 years, 21–29% exhibit aortic valve sclerosis. Incidence of aortic sclerosis increases with age, male gender, smoking, hypertension, high lipoprotein (Lp) (a), high low‐density lipoprotein (LDL), and diabetes mellitus. Aortic valves affected by aortic sclerosis contain a higher amount of oxidized LDL cholesterol and show increased expression of metalloproteinases. Clinically, it can be suspected in the presence of soft ejection systolic murmur at the aortic area, normal split of the second heart sound, and normal volume carotid pulse, but it can be best detected by echocardiography. Aortic sclerosis may be accompanied by mitral annulus calcification up to 50% of cases. It is associated with an increase of approximately 50% in the risk of death from cardiovascular causes and the risk of myocardial infarction. The mechanism by which aortic sclerosis contributes to or is associated with increased cardiovascular risk is not known. Aortic sclerosis is associated with systemic endothelial dysfunction, and a small percentage of cases may progress to aortic stenosis. Lowering of LDL cholesterol by 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors have been shown to decrease progression of aortic valve calcification. Aortic sclerosis is not a mere benign finding. Once diagnosis of aortic sclerosis has been made, it should be considered a potential marker of coexisting coronary disease. Aggressive management of modifiable risk factors, especially LDL cholesterol lowering, may slow progression of the disease.
Keywords: aortic valve sclerosis, coronary atherosclerosis, cardiovascular events, risk modification
Full Text
The Full Text of this article is available as a PDF (43.9 KB).
References
- 1. Lindroos M, Kupari M, Heikkila J, Tilvis R: Prevalence of aortic valve abnormalities in the elderly: An echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220–1225 [DOI] [PubMed] [Google Scholar]
- 2. Gardin JM, Wong ND, Bommer W, Klopfenstein HS, Smith VE, Tabatznik B, Siscovick D, Lobodzinski S, Anton‐Culver H, Manolio TA: Echocardiographic design of amulticenter investigation of free‐living elderly subjects: The Cardiovascular Health Study. J Am Soc Echocardiogr 1992; 5: 63–72 [DOI] [PubMed] [Google Scholar]; [Erratum, J Am Soc Echocardiogr 1992; 5: 550.] [Google Scholar]
- 3. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM: Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630–634 [DOI] [PubMed] [Google Scholar]
- 4. Deutscher S, Rockette HE, Krishnaswami V: Diabetes and hypercholes‐terolemia among patients with calcific aortic stenosis. J Chron Dis 1984; 37: 407–415 [DOI] [PubMed] [Google Scholar]
- 5. Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y, Nagoh N, Kayaba K, Yamada S, Matsuo H: Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76: 928–932 [DOI] [PubMed] [Google Scholar]
- 6. Aronow WS, Schwartz KS, Koenigsberg M: Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59: 998–999 [DOI] [PubMed] [Google Scholar]
- 7. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM: Apolipoproteins B, (a), and Eaccumulate in the morphologically early lesion of “degenerative” valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16: 523–532 [DOI] [PubMed] [Google Scholar]
- 8. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE, Otto CM: Osteopontin is expressed inhuman aortic valvular lesions. Circulation 1995; 92: 2163–2168 [DOI] [PubMed] [Google Scholar]
- 9. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J: Accumulation of T lymphocytes and expression of interleukin‐2 receptors innonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994; 23: 1162–1170 [DOI] [PubMed] [Google Scholar]
- 10. Olsson M, Rosenqvist M, Nilsson J: Expression of HLA‐DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol 1994; 24: 1664–1671 [DOI] [PubMed] [Google Scholar]
- 11. Boon A, Cheriex E, Lodder J, Kessels F: Cardiac valve calcification: Characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997; 78: 472–474 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A: The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1991; 1: 263–276 [DOI] [PubMed] [Google Scholar]
- 13. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS: Association of aortic‐valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341: 142–147 [DOI] [PubMed] [Google Scholar]
- 14. Teerlink JR, Newman TB, Schiller NB, Foster E: Aortic sclerosis, as well as aortic stenosis, is a significant predictor of mortality (abstr). Circulation 1997; 96; (suppl I): 1–82 [Google Scholar]
- 15. Aronow S, Ahn C, Kronzon I: Association of mitral annular calcium and of aortic cuspal calcium with coronary artery disease in older patients. Am J Cardiol 1999; 84: 1084–1085 [DOI] [PubMed] [Google Scholar]
- 16. Carabello BA: Aortic sclerosis—window to the coronary arteries? N Engl J Med 1999; 341: 193–195 [DOI] [PubMed] [Google Scholar]
- 17. Poggianti E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E: Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol 2003. Jan 1; 41 (1): 136–141 [DOI] [PubMed] [Google Scholar]
- 18. Adler Y, Vaturi M, Herz I, Iakobishvili Z, Toaf J, Fink N, Battler A, Sagie A: Nonobstructive aortic valve calcification: A window to significant coronary artery disease. Atherosclerosis 2002; 161: 193–197 [DOI] [PubMed] [Google Scholar]
- 19. Fox CSD, Vasan RS, Parise H, Levy D, O'Donnell CJ, D'Agostino RB, Benjamin EJ: Mitral annular calcification predicts cardiovascular morbidity and mortality: The Framingham Heart Study. Circulation 2003; 107 (11): 1492–1496 [DOI] [PubMed] [Google Scholar]
- 20. Otto CM, Burwash IG, Legget ME, Munt BE, Fujioka M, Healy NL, Kraft CD, Miyake‐Hull CY, Schwaegler RG: Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95: 2262–2270 [DOI] [PubMed] [Google Scholar]
- 21. Otto CM, Pearlman AS, Gardner CL: Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Cardiol 1989; 13: 545–550 [DOI] [PubMed] [Google Scholar]
- 22. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H: Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343: 611–617 [DOI] [PubMed] [Google Scholar]
- 23. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG‐CoA reductase inhibitors on coronary artery disease as assessed by electron‐beam computed tomography. N Engl J Med 1998;Dec 31, 339: 1972–1978 [DOI] [PubMed] [Google Scholar]
- 24. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD: HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; (9312): 1125–1126 [DOI] [PubMed]